The International Contrast Ultrasound Society (ICUS)

Bracco's Lumason contrast agent approved by FDA

Bracco Diagnostics has received approval for its Lumason ultrasound contrast agent, which now joins Definity (Lantheus Medical Imaging) and Optison (GE Healthcare) as approved ultrasound contrast agents in the U.S. Known previously as SonoVue, Lumason (sulfur hexafluoride lipid microbubbles) is indicated for patients whose echocardiography images are hard to see with ultrasound, according to the FDA.

Click here for full FDA statement:

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:



Toshiba Medical logo resized





ICUS Tweets

Follow Bubble Conference 2016 comment at #bubble2016
Connect live now to the 31st Annual Advances in Contrast Ultrasound "Bubble Conference" taking place in Chicago;
FDA approves new liver imaging agent for adults and children; reduces exposure to harmful radiation. More at:

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News Bracco's Lumason contrast agent approved by FDA